Skip to main content
SpringerLink
Log in

Eye Medications and Its Effect on Orbital Fat and Cosmesis

  • Chapter
  • First Online:
Periorbital Rejuvenation

  • 475 Accesses

Abstract

Different eye medications could affect eye cosmesis or orbital fat. These medications includes; preservatives that are present in eye drops including artificial tears and glaucoma drop, active ingredients in glaucoma medications itself. Peribulbar injections of steroids that used to treat some ocular disease can also affect periocular eye fat.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–83.

    Article  PubMed  Google Scholar 

  2. Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71–81.

    PubMed  PubMed Central  Google Scholar 

  3. Dry Eye Workshop. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop. Ocul Surf. 2007;5(2):75–92.

    Article  Google Scholar 

  4. Pauly A, Brasnu E, Riancho L, Bringole-Baudouin F, Badouin C. Multiple endpoint analysis of BAC-preserved and unpreserved antiallergic eye drops on a 3D-reconstituted corneal epithelial model. Mol Vis. 2011;17:745–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Rosin LM, Bell NP. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. Clin Ophthalmol. 2013;7:2131–5.

    PubMed  PubMed Central  Google Scholar 

  6. Noecker R, Miller KV. Benzalkonium chloride in glaucoma medications. Ocul Surf. 2011;9(3):159–62.

    Article  PubMed  Google Scholar 

  7. Miljanovic B, Dana R, Sullivan DA, et al. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143:409–15.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Miyake K, Ota I, Ibaraki N, et al. Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macula edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol. 2001;119(3):387–94.

    Article  CAS  PubMed  Google Scholar 

  9. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology. 1989;96(3):327–35.

    Article  CAS  PubMed  Google Scholar 

  10. Inoue K, et al. Ocular hypotensive effects and safety of latanoprost without benzalkonium hydrochloride. Atarashii Ganka (J Eye). 2011;28(11):1635–9. Japanese.

    Google Scholar 

  11. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol. 2007;18:134–9.

    Article  PubMed  Google Scholar 

  12. Takahashi N. Quantitative cytotoxicity of preservatives evaluated in cell culture with Chang’s human conjunctival cells—effect of temperature on cytotoxicity. Jpn J Ophthalmol. 1982;26:234–8.

    CAS  PubMed  Google Scholar 

  13. Wilson FM II. Adverse external ocular effects of topical ophthalmic therapy: an epidemiologic, laboratory, and clinical study. Trans Am Ophthalmol Soc. 1983;81:854–965.

    PubMed  PubMed Central  Google Scholar 

  14. Rossi GCM, Scudeller L, Rolle T, Pasinetti GM, Bianchi PE. From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability. Expert Opin Drug Saf. 2015;14(5):619–23.

    Google Scholar 

  15. Collaborative Normal-Tension Glaucoma Study-Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126(4):498–505.

    Article  Google Scholar 

  16. The AGIS. Investigators. The Advanced glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2008;130(4):429–40.

    Google Scholar 

  17. Inoue K, Shiokawa M, Higa R, et al. Adverse periocular reactions to five types of prostaglandin analogs. Eye. 2012;26(11):1465–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Inoue K, Wakakura M, Inoue J, et al. [Adverse reaction after use of latanoprost in Japanese glaucoma patients]. Nihon Ganka Gakkai Zasshi. 2006;110(8):581–7. Japanese.

    Google Scholar 

  19. Inoue K, Shiokawa M, Wakakura M, Tomita G. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma. 2013;22(8):626–31.

    Article  PubMed  Google Scholar 

  20. Honrubia F, García-Sánchez J, Polo V, de la Casa JM, Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: meta-analysis of randomized clinical trials. Br J Ophthalmol. 2009;93(3):316–21.

    Article  CAS  PubMed  Google Scholar 

  21. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs. A meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008;17(8):667–73.

    Article  PubMed  Google Scholar 

  22. Eyawo O, Nachega J, Lefebvre P, et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol. 2009;3:447–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Crichton AC, Vold S, Williams JM, Hollander DA. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension. Adv Ther. 2013;30(3):260–70.

    Article  CAS  PubMed  Google Scholar 

  24. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124(4):554–47.

    Article  Google Scholar 

  25. Wester ST, Lee WW, Shi W. Eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes. Ophthalmology. 2010;117(5):1024–31.

    Article  PubMed  Google Scholar 

  26. Giannico AT, Lima L, Russ HH, Montiani-Ferreira F. Eyelash growth included by topical prostaglandin analogues, bimatoprost, travoprost, travoprost and latanoprost in rabbits. J Ocular Pharmacol Ther. 2013;29(9):817–20.

    Article  CAS  Google Scholar 

  27. Casson RJ, Selva D. Lash ptosis caused by latanoprost. Am J Ophthalmol. 2005;139:932–3.

    Article  PubMed  Google Scholar 

  28. Priluck JC, Fu S. Latisse-included periocular skin hyperpigmentation. Arch Ophthalmol. 2010;128(6):792–3.

    Article  PubMed  Google Scholar 

  29. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology. 1996;103(11):1916–24.

    Article  CAS  PubMed  Google Scholar 

  30. Peplinski LS, Albiani SK. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81(8):574–7.

    Article  PubMed  Google Scholar 

  31. Filippopoulos T, et al. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg 24(4):302–7.

    Google Scholar 

  32. Romano MR, Lograno MD. Evidence for the involvement of cannabinoid CB1 receptors in the bimatoprost-induced contractions on the human isolated ciliary muscle. Invest Ophthalmol Vis Sci. 2007;48(8):3677–82.

    Article  PubMed  Google Scholar 

  33. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. Nature. 2008;453(7196):783–7.

    Article  CAS  PubMed  Google Scholar 

  34. Arner P. Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab. 2005;19:471–82.

    Article  CAS  PubMed  Google Scholar 

  35. Crowston JG, Lindsey JD, Morris CA, et al. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice. Invest Ophthalmol Vis Sci. 2005;46:4571–7.

    Article  PubMed  Google Scholar 

  36. Serrero G, Lepak NM. Prostaglandin F2alpha receptor (FP receptor) agonists are potent adipose differentiation inh Miller CW, Casimir DA, Ntambi JM. The mechanism of inhibition of 3T3–L1 preadipocyte differentiation by prostaglandin F2alpha. Endocrinology. 1996;137:5641–50.

    Article  Google Scholar 

  37. Serrero G, Lepak NM. Prostaglandin F2alpha receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochem Biophys Res Commun 1997;233:200–2.

    Google Scholar 

  38. Woodward DF, Krauss AH, Chen J, et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther. 2003;305:772–85.

    Article  CAS  PubMed  Google Scholar 

  39. Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011;55(1):22–7.

    Article  CAS  PubMed  Google Scholar 

  40. Shah M, Lee G, Lefebvre DR, et al. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013;8(5):e61638.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol. 1999;127(5):602–4.

    Article  CAS  PubMed  Google Scholar 

  42. Miyake K, Ota I, Maekubo K, Ichihashi S, Miyake S. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol. 1999;117(1):34–40.

    Article  CAS  PubMed  Google Scholar 

  43. Inoue K, Okugawa K, Kato S, et al. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma. 2003;12(6):480–5.

    Article  PubMed  Google Scholar 

  44. Toris CB, Tafoya ME, Camras CB, Yablonski ME. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology. 1995;102(3):456–61.

    Article  CAS  PubMed  Google Scholar 

  45. Abrams DA, Robin AL, Polack IP. deFaller JM, DeSantis L. The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers. Arch Ophthalmol. 1987;105(9):1205–7.

    Article  CAS  PubMed  Google Scholar 

  46. Butler P, Mannschreck M, Lin S, Hwang I, Alvaeado J. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol. 1995;113(3):293–6.

    Article  CAS  PubMed  Google Scholar 

  47. Litcher PR, Newman LP, Wheeler NC, Beall OV. Patient tolerance to carbonic anhydrase inhibitors. Am J Ophthalmol. 1978;85(4):495–502.

    Article  Google Scholar 

  48. Strahlman E, Tipping R, Voqel R. International Dorzolamide Study Group: A double-masked, randomized 1-year study comparing dorzolamide (Trusport), timolol, and betaxolol. Arch Ophthalmol. 1995;113(8):1009–16.

    Article  CAS  PubMed  Google Scholar 

  49. Silver LH. Brizolamide Comfort Study Group: Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results for two multicenter comfort studies. Surv Ophthalmol. 2000;44:S141–5.

    Google Scholar 

  50. Konowal A, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999;127(4):403–6.

    Article  CAS  PubMed  Google Scholar 

  51. Zimmerman TJ, Wheeler TM. Miotics: side effects and ways to avoid them. Ophthalmology. 1982;89(1):76–80.

    Article  CAS  PubMed  Google Scholar 

  52. Kopczynski CC, Heah, T. Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension. Drugs Today 2018; 54(8): 467

    Google Scholar 

  53. Serle JB, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2).Am J Ophthalmol. 2018;186:116–27.

    Google Scholar 

  54. Kaimbo Wa Kaimbo D, Nkidiaka MC. [Intralesional corticosteroid injection in the treatment of chalazion]. J Fr Ophtalmol. 2004;27(2):149–53.

    Google Scholar 

  55. Kushner BJ. Local steroid therapy in adnexal hemangioma. Ann Ophthalmol. 1979;11:1005–9.

    CAS  PubMed  Google Scholar 

  56. Hosal BM, Zilelioglu G. Ocular complication of intralesional corticosteroid injection of a chalazion. Eur J Ophthalmol. 2003;13:798–9.

    Article  CAS  PubMed  Google Scholar 

  57. Fogla R, Rao SK, Biswas J. Avoiding conjunctival necrosis after periocular depot corticosteroid injection. J Cataract Refractive Surg. 2000;26:163–4.

    Article  CAS  Google Scholar 

  58. Jabs DA. A prospective evaluation of subconjunctival injection of triamcinolone acetonide for resistant anterior scleritis (Discussion by Ds A Jabs). Ophthalmology. 2002;109:806–7.

    Article  Google Scholar 

  59. Moshfeghi DM, Lowder CY, Roth DB, Kaiser PK. Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am J Ophthalmol. 2002;134:132–4.

    Article  PubMed  Google Scholar 

  60. Gupta OP, Boynton JR, Sabini P, et al. Proptosis after retrobulbar corticosteroid injections. Ophthalmology. 2003;110:443–7.

    Article  PubMed  Google Scholar 

  61. Gregoire F, Genart C, Hauser N, Remacle C. Glucocorticoids induce a drastic inhibition of proliferation and stimulate differentiation of adult rat fat cell precursors. Exp Cell Res. 1991;196:270–8.

    Article  CAS  PubMed  Google Scholar 

  62. Droste PJ, Ellis FD, Sondhi N, Helveston EM. Linear subcutaneous fat atrophy after corticosteroid injection of periocular hemangiomas [case report]. Am J Ophthalmol. 1988;105:65–9.

    Article  CAS  PubMed  Google Scholar 

  63. Townshend LM, Buckley EG. Linear subcutaneous fat atrophy after a single corticosteroid injection for ocular adnexal hemangioma [case report]. Am J Ophthalmol. 1990;109:102–3.

    Article  CAS  PubMed  Google Scholar 

  64. Iuel J, Kryger J. Local cutaneous atrophy following corticosteroid injection [case report]. Acta Rheum Scand. 1965;11:137–44.

    Article  CAS  PubMed  Google Scholar 

  65. Reddy PD, Zelicof SB, Ruotolo C, Holder J. Interdigital neuroma. Local cutaneous changes after corticosteroid injection [case report]. Clin Orthop. 1995;317:185–7.

    Google Scholar 

  66. Nozik RA. Orbital rim fat atrophy after repository periocular corticosteroid injection [case report]. Am J Ophthalmol. 1976;82:928–30.

    Article  CAS  PubMed  Google Scholar 

  67. Brancaccio RR, Zappi EG. Delayed type hypersensitivity to intralesional triamcinolone acetonide [case report]. Cutis. 2000;65:31–3.

    CAS  PubMed  Google Scholar 

  68. Downs AM, Lear JT, Kennedy CT. Anaphylaxis to intradermal triamcinolone acetonide [case report]. Arch Dermatol. 1998;134:1163–4.

    Article  CAS  PubMed  Google Scholar 

  69. Koornneef L. New insights in the human orbital connective tissue. Result of a new anatomical approach. Arch Ophthalmol. 1977;95:1269–1273.

    Google Scholar 

  70. Gupta OP, et al. Proptosis after retrobulbar corticosteroid injections. Ophthalmology. 2003;110:443–7.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Hospital of Geneva (HUG), Geneva, Switzerland

    Tarek Shaarawy

  2. Glaucoma Unit, Research Institute of Ophthalmology (RIO), Giza, Egypt

    Amr Aref

Authors
  1. Tarek Shaarawy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amr Aref
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tarek Shaarawy .

Editor information

Editors and Affiliations

  1. National Institute of Laser Enhanced Sciences, Cairo University, Giza, Egypt

    Ashraf Badawi

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Shaarawy, T., Aref, A. (2020). Eye Medications and Its Effect on Orbital Fat and Cosmesis. In: Badawi, A. (eds) Periorbital Rejuvenation. Springer, Cham. https://doi.org/10.1007/978-3-030-46866-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-46866-8_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-46865-1

  • Online ISBN: 978-3-030-46866-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation